RIPE-KG · Version 1.1.0 · Resource

ripekg:registry-evidence/RIPEAA805A88D874EA69C

https://w3id.org/ripe/ripe-kg/registry-evidence/RIPEAA805A88D874EA69C

Subject	Predicate	Object
`ripekg:evaluation/RIPEAA805A88D874EA69C`	`prov:used`	`ripekg:registry-evidence/RIPEAA805A88D874EA69C`
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`rdf:type`	`rdfs:Resource`
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`rdf:type`	`owl:Thing`
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`rdf:type`	`ripe:IntegrityAssessmentEvidence`Integrity assessment evidence
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`rdf:type`	`ripe:RegistryEvidence`Registry evidence
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`rdf:type`	`tido:Evidence`
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`prov:wasGeneratedBy`	`ripekg:evidence-aggregation/RIPEAA805A88D874EA69C`
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEAA805A88D874EA69C`
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`ripe:concerns`	`ripekg:work/10.1007%2Fs13318-014-0242-5`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`ripe:registrationAssessmentRationale`	LLM-extracted recruitment start date (normalized_date) is missing or empty.
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEAA805A88D874EA69C-human-2-2`
`ripekg:registry-evidence/RIPEAA805A88D874EA69C`	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEAA805A88D874EA69C-inspectai-2-2`